Eli Lilly CEO's Total Compensation Rose 10% in 2024
Eli Lilly Chief Executive David Ricks annual compensation rose to $29.2 million in 2024, a 10% increase from the $26.2 million he received a year earlier.
The drugstore industry is struggling. Here's what could be in its future.
But as the drugstore chain (WBA) prepares to go private and its rival CVS Health Inc. (CVS) experiments with smaller stores, some analysts and researchers see a possible future with even fewer ...
This five-star all-weather ETF can lower your exposure to risky stocks and bonds
The overall returns have pretty much been the same, with HGER and SPY trailing the S&P 500 slightly - the index has no fund-manager expenses. But HGER has provided a smoother ride for investors, as it ...
Ozempic parent's new weight-loss drug works better, but not quite good enough
CagriSema, which is a combination of cagrilintide 2.4-milligram and semaglutide 2.4-mg doses, is being developed so people have a better choice for a weight-loss drug when the patents on Ozempic and ...
Morningstar5d
Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
Lilly will present additional data from the BRAVE-AA-PEDS study at scientific meetings later this year and submit the results for peer-reviewed publication. Baricitinib is a once-daily ...
Health Care Down on Rotation Back to Risk — Health Care Roundup
Health-care companies fell as traders rotated back into higher risk areas. Swiss drug giant Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion ...
Roche takes big step in weight-loss field with $5.3 billion deal.
Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to Zealand Pharma in a licensing and development agreement.
Here's why Ozempic maker's new weight-loss drug isn't good enough for investors
Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy, the diabetes and obesity treatments, revealed data showing that its new weight-loss drug candidate ...
I invested $4,000 in 2020. It's now worth $55,000 with a 65% concentration in Nvidia. What now?
Now, that account is worth $55,000, with a 65% concentration in Nvidia (NVDA), which was my first stock buy, then a 20% concentration in Novo Nordisk (NVO) and Eli Lilly (LLY) stock, with 15% ...
Roche takes big step in weight-loss field with $5.3 billion deal. Novo Nordisk shares fall.
Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to Zealand Pharma in a licensing and development agreement. Zealand Pharma's ...
BioNTech's mRNA Technology and Acquired Oncology Programs Could Support a Future Moat
The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...